- Lexaria
Bioscience is focusing on its unique technology for the delivery of
bioactive compounds
- The
company’s concentration on oral ingestion results in an option that often
healthier than other delivery methods
- Its
DehydraTECH technology has potential applications for nicotine absorption
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) focuses
on technology for the improved delivery of bioactive compounds. Its DehydraTECH
drug delivery platform fosters healthier administration methods, lower overall
dosing and higher effectiveness of ingestible drugs and other beneficial molecules.
The company’s process changes the way edible cannabinoids enter the body (http://ibn.fm/CB41E). A drug
delivery innovator, Lexaria Bioscience is headquartered in Kelowna, British
Columbia.
Lexaria’s technology has been shown to be effective in
numerous global studies, significantly assisting rapidity and quantity of
absorption for a range of lipophilic (fat-soluble), bioactive molecules. In
essence, the company disrupts the manner in which cannabinoids enter the
bloodstream through the gastrointestinal tract (http://ibn.fm/CsUCz). Lexaria’s
emphasis on oral ingestion provides a practical and often healthier option to
other delivery methods for bioactive substances used extensively today. This
includes inhalational delivery via smoking.
The DehydraTECH platform masks taste, lessens the time of
onset and increases bio-absorption by 5-10 times. The technology is patent
protected for cannabidiol and all other non-psychoactive cannabinoids. Lexaria
has patents pending for THC, nonsteroidal anti-inflammatory drugs (NSAIDs),
nicotine, other psychoactive cannabinoids and other molecules. These patents
apply to manifold consumer/pharma product dosage forms and include food liquid
emulsions, capsules, tablets and more.
The Lexaria Hemp Co. holds exclusive international rights to
the Lexaria patent portfolio related to hemp-based applications. Moreover, its
Canadian subsidiary, Lexaria CanPharm Corp., owns exclusive international
rights to Lexaria’s intellectual property that’s applicable to psychotropic
bioactive molecules, which act upon human CB1 and CB2 receptors in those global
geographic areas where it is permissible to do so (http://ibn.fm/d2roZ).
Lexaria Bioscience’s business model involves developing and
out-licensing its DehydraTECH platform to third-party
partners/distributors (http://ibn.fm/Bx1uI).
In addition, its business model involves the sale of Lexaria-developed and
joint venture products. The company’s product sales include hemp oil-based CBD
(cannabidiol) offerings. Its TurboCBD hemp oil capsules contain ginseng and
ginkgo to promote better focus and memory and have been evaluated in clinical
tests.
Lexaria’s product sales additionally include ViPova-branded
premium teas. These teas deliver cannabidiol in a number of flavors and have
been available for several years, showcasing Lexaria’s leadership position in
beverage formulations.
Lexaria Bioscience has a collaborative research agreement
with Canada’s National Research Council. This research agreement is to
investigate opportunities associated with bioavailability enhancement of
lipophilic active ingredient compositions (http://ibn.fm/UP5RO).
Lexaria Bioscience has engaged in research regarding the use
of its technology for nicotine absorption, relating to the nicotine industry.
It has partnered, via wholly owned subsidiary Lexaria Nicotine LLC, with one of
the world’s largest tobacco companies to drive innovation in oral, reduced risk
nicotine consumer products using the patented DehydraTECH drug delivery
platform (http://ibn.fm/IHDmy).
Lexaria Nicotine aims to perform a wide-ranging series of clinical
investigations of oral forms of nicotine delivery, funded by its partner,
employing Lexaria’s patented DehydraTECH technology.
Lexaria Bioscience continues its R&D for the improved
delivery of bioactive compounds. The company offers investors the potential to
earn ROI from its disruptive technology in the emerging market of low cost
edibles. Lexaria continues to advance its technology that enables consumer
benefits and the lowest cost-per-serving.
For more information, visit the company’s website at www.LexariaBioscience.com
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
